ライフサイエンスコーパス: lung disorder

1 ment of therapies to prevent smoking-related lung disorders).

2 in-2 deficiency is the clear culprit in this lung disorder.

3 icrobial communities associated with chronic lung disorders.

4 diseases, with a focus on cardiovascular and lung disorders.

5 cholestatic liver diseases, and inflammatory lung disorders.

6 tial therapeutic avenues in the treatment of lung disorders.

7 irway surfaces of patients with inflammatory lung disorders.

8 athogenesis of a number of acute and chronic lung disorders.

9 he expression of MME by Mphi in inflammatory lung disorders.

10 ory distress syndrome and other inflammatory lung disorders.

11 ructive pulmonary disease and other advanced lung disorders.

12 to viral infections associated with chronic lung disorders accompanied by chronic goblet cell metapl

13 ical tools in patients with asthma and other lung disorders and to explore some of the new developmen

14 ses including neurodevelopmental, renal, and lung disorders, and cancer.

15 ion and five of six patients without primary lung disorder but in only one of six with parenchymal lu

16 ill include the cure of the major hereditary lung disorders by gene therapy, new treatment for asthma

17 c beryllium disease (CBD) is a granulomatous lung disorder caused by a hypersensitivity to beryllium

18 hronic beryllium disease (CBD) is a fibrotic lung disorder caused by beryllium (Be) exposure and is c

19 Chronic beryllium disease is a lung disorder caused by beryllium exposure in the workpl

20 Asthma is a heterogeneous lung disorder characterized by airway inflammation and a

21 n chronic beryllium disease, a granulomatous lung disorder characterized by CD4(+) T cell alveolitis

22 c beryllium disease (CBD) is an occupational lung disorder characterized by granulomatous inflammatio

23 airway obstruction) and six without primary lung disorder (Group 2).

24 These data establish that certain lung disorders, if of cell-autonomous hematopoietic orig

25 lmonary alveolar proteinosis (PAP) is a rare lung disorder in which surfactant-derived lipoproteins a

26 0 patients under neuromuscular blockade with lung disorders including moderately severe restrictive (

27 ngoing clinical research networks with other lung disorders, including acute respiratory distress syn

28 ung induces features of chronic inflammatory lung disorders, including an eosinophil-rich inflammator

29 scription factors are upregulated in chronic lung disorders, including asthma.

30 ary fibrosis is a common feature of numerous lung disorders, including interstitial lung diseases, as

31 remodeling of the ECM occurs during several lung disorders, it is not known how fiber structure and

32 Despite the importance of fibroproliferative lung disorders, no safe and effective therapies exist fo

33 Sarcoidosis is a granulomatous lung disorder of unknown cause.

34 iopathic pulmonary fibrosis is a devastating lung disorder of unknown etiology.

35 nary fibrosis (IPF) is a chronic progressive lung disorder of unknown etiology.

36 is for combination therapies in interstitial lung disorders other than idiopathic pulmonary fibrosis.

37 to IPF and also occur in other aging-related lung disorders, primarily chronic obstructive pulmonary

38 e effects of IL-36 cytokines in inflammatory lung disorders remains poorly understood.

39 -CSF, interleukin (IL)-3, and IL-5 exhibit a lung disorder similar to human pulmonary alveolar protei

40 uld revolutionise treatment of patients with lung disorders such as cancer, acute respiratory distres

41 metalloelastase (MME) has been implicated in lung disorders such as emphysema and pulmonary fibrosis,

42 Pulmonary fibrosis is a serious lung disorder that can lead to respiratory failure.

43 (ARDS) is a relatively common, inflammatory lung disorder that is associated with major morbidity an

44 ic beryllium (Be) disease is a granulomatous lung disorder that results from Be exposure in a genetic

45 g diseases encompass a wide range of diffuse lung disorders that are often complicated by the develop

46 represent two classes of chronic obstructive lung disorders that may share some similar immunologic m

47 ts), disease progression (two patients), and lung disorder (two patients).

48 pathophysiologic processes of fiber-induced lung disorders was examined.

49 onary fibrosis (IPF) is a morbid, refractory lung disorder with an unknown pathogenesis.

50 ic pulmonary fibrosis (IPF) is a devastating lung disorder with increasing incidence.

51 pulmonary fibrosis (IPF) is a fatal fibrotic lung disorder with no effective medical treatments avail